These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35026155)

  • 1. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19.
    Bi X; Liu W; Ding X; Liang S; Zheng Y; Zhu X; Quan S; Yi X; Xiang N; Du J; Lyu H; Yu D; Zhang C; Xu L; Ge W; Zhan X; He J; Xiong Z; Zhang S; Li Y; Xu P; Zhu G; Wang D; Zhu H; Chen S; Li J; Zhao H; Zhu Y; Liu H; Xu J; Shen B; Guo T
    Cell Rep; 2022 Jan; 38(3):110271. PubMed ID: 35026155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19-specific metabolic imprint yields insights into multiorgan system perturbations.
    Cornillet M; Strunz B; Rooyackers O; Ponzetta A; Chen P; Muvva JR; Akber M; Buggert M; Chambers BJ; Dzidic M; Filipovic I; Gorin JB; Gredmark-Russ S; Hertwig L; Klingström J; Kokkinou E; Kvedaraite E; Lourda M; Mjösberg J; Maucourant C; Norrby-Teglund A; Parrot T; Perez-Potti A; Rivera-Ballesteros O; Sandberg JK; Sandberg JT; Sekine T; Svensson M; Varnaite R; ; Eriksson LI; Aleman S; Strålin K; Ljunggren HG; Björkström NK
    Eur J Immunol; 2022 Mar; 52(3):503-510. PubMed ID: 34837225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts.
    Tristán AI; Jiménez-Luna C; Abreu AC; Arrabal-Campos FM; Salmerón ADM; Rodríguez FI; Maresca MÁR; García AB; Melguizo C; Prados J; Fernández I
    Sci Rep; 2024 Oct; 14(1):23713. PubMed ID: 39390047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.
    Villar M; Urra JM; Rodríguez-Del-Río FJ; Artigas-Jerónimo S; Jiménez-Collados N; Ferreras-Colino E; Contreras M; de Mera IGF; Estrada-Peña A; Gortázar C; de la Fuente J
    Front Immunol; 2021; 12():730710. PubMed ID: 34566994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19.
    Costanzo M; Caterino M; Fedele R; Cevenini A; Pontillo M; Barra L; Ruoppolo M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
    Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
    Front Immunol; 2021; 12():738093. PubMed ID: 34777349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.
    Rendeiro AF; Vorkas CK; Krumsiek J; Singh HK; Kapadia SN; Cappelli LV; Cacciapuoti MT; Inghirami G; Elemento O; Salvatore M
    Front Immunol; 2021; 12():809937. PubMed ID: 35095900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.
    Wu M; Chen Y; Xia H; Wang C; Tan CY; Cai X; Liu Y; Ji F; Xiong P; Liu R; Guan Y; Duan Y; Kuang D; Xu S; Cai H; Xia Q; Yang D; Wang MW; Chiu IM; Cheng C; Ahern PP; Liu L; Wang G; Surana NK; Xia T; Kasper DL
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28336-28343. PubMed ID: 33082228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological conditions can be reflected in human urine proteome and metabolome.
    Wu J; Gao Y
    Expert Rev Proteomics; 2015; 12(6):623-36. PubMed ID: 26472227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of metalloproteome and immunoproteome reveals a tight link of iron-related proteins with COVID-19 pathogenesis and immunity.
    Zhou Y; Cheng T; Tang K; Li H; Luo C; Yu F; Xiao F; Jin L; Hung IF; Lu L; Yuen KY; Chan JF; Yuan S; Sun H
    Clin Immunol; 2024 Jun; 263():110205. PubMed ID: 38575044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
    Georg P; Astaburuaga-García R; Bonaguro L; Brumhard S; Michalick L; Lippert LJ; Kostevc T; Gäbel C; Schneider M; Streitz M; Demichev V; Gemünd I; Barone M; Tober-Lau P; Helbig ET; Hillus D; Petrov L; Stein J; Dey HP; Paclik D; Iwert C; Mülleder M; Aulakh SK; Djudjaj S; Bülow RD; Mei HE; Schulz AR; Thiel A; Hippenstiel S; Saliba AE; Eils R; Lehmann I; Mall MA; Stricker S; Röhmel J; Corman VM; Beule D; Wyler E; Landthaler M; Obermayer B; von Stillfried S; Boor P; Demir M; Wesselmann H; Suttorp N; Uhrig A; Müller-Redetzky H; Nattermann J; Kuebler WM; Meisel C; Ralser M; Schultze JL; Aschenbrenner AC; Thibeault C; Kurth F; Sander LE; Blüthgen N; Sawitzki B;
    Cell; 2022 Feb; 185(3):493-512.e25. PubMed ID: 35032429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omic profiling of plasma reveals molecular alterations in children with COVID-19.
    Wang C; Li X; Ning W; Gong S; Yang F; Fang C; Gong Y; Wu D; Huang M; Gou Y; Fu S; Ren Y; Yang R; Qiu Y; Xue Y; Xu Y; Zhou X
    Theranostics; 2021; 11(16):8008-8026. PubMed ID: 34335977
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
    Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH
    J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    ;
    Cell; 2022 Mar; 185(5):916-938.e58. PubMed ID: 35216673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic Biomarkers to Guide Stratification for Covid-19 Treatment: Exemplifying a Path Forward Toward Implementation?
    Jankowski J
    Proteomics; 2020 Dec; 20(24):e2000229. PubMed ID: 33141520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in understanding COVID-19: insights from the omics approach.
    Lin B; Liu J; Liu Y; Qin X
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):242-252. PubMed ID: 33375876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary proteomics and metabolomics in the diagnosis of pediatric disorders.
    Vaidyanathan K
    Proteomics Clin Appl; 2015 Jun; 9(5-6):482-9. PubMed ID: 25631340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic and features of SARS-CoV-2 infection in Gabon.
    Mveang Nzoghe A; Padzys GS; Maloupazoa Siawaya AC; Kandet Yattara M; Leboueny M; Avome Houechenou RM; Bongho EC; Mba-Mezeme C; Mvoundza Ndjindji O; Biteghe-Bi-Essone JC; Boulende A; Essone PN; Ndong Sima CAA; Minkobame U; Zang Eyi C; Ndeboko B; Voloc A; Meye JF; Ategbo S; Djoba Siawaya JF
    Sci Rep; 2021 May; 11(1):9672. PubMed ID: 33958601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics study of COVID-19 patients in four different clinical stages.
    Valdés A; Moreno LO; Rello SR; Orduña A; Bernardo D; Cifuentes A
    Sci Rep; 2022 Jan; 12(1):1650. PubMed ID: 35102215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.